Belmore is the brand of Bempedoic acid, one of its kind novel drug for the management of high LDL
cholesterol is going to be launched for the first time in India by Cadila Pharmaceuticals, Ahmedabad.
Dyslipidaemia is a condition where blood levels of bad cholesterol (LDL and Triglycerides) are beyond
normal. This can lead to serious life-threatening heart complications due to blockage in blood
vessels. As per some published data, more than 25% of urban adults and 15% of rural adults in India
are suffering from this silent disease. Currently, statins are the group of drugs used to control the
disease, but in more than 50% of patients, these drugs are either not giving optimum control or are
not tolerated.
Bempedoic acid (Belmore) is meant to provide additional benefits to these patients. All pre-launch
studies have established this advantage. Cadila Pharmaceuticals being the market leader in the
management of cardiovascular disease with its innovative products has stepped further in this war
by launching Belmore for the first time for Indian patients.